TuHURA Biosciences, Inc.
HURAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 27, 2026 |
| Citizens | maintain | Market Outperform | Aug 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| Maxim Group | maintain | Buy | Nov 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2025 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.14 | $-0.15 | — | — |
| May 15, 2026 | $-0.13 | $-0.12 | — | — |
| Mar 31, 2026 | $-0.13 | $-0.12 | — | — |
| Nov 14, 2025 | $-0.14 | $-0.15 | — | — |
| Aug 14, 2025 | $-0.21 | $-0.14 | — | — |
| May 15, 2025 | $-0.15 | $-0.13 | — | — |
| Feb 26, 2025 | $-8.39 | $-0.09 | — | — |
| Nov 14, 2024 | $-1.37 | $-0.10 | — | $6.3M |
News
Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages TAMPA, Fla., Nov. 4, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to canc…
TuHURA Biosciences NASDAQ: HURA presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting.
Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ET TAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive the…
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies TAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No.
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cance…
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A.
TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript
TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.